Zyprexa Intramuscular en es it fr

Categoria

Zyprexa Intramuscular Marchi, Zyprexa Intramuscular Analoghi

Zyprexa Intramuscular Marchi miscela

  • No information avaliable
  • Zyprexa Intramuscular Formula chimica

    C17H20N4S

    Zyprexa Intramuscular RX link

    http://www.rxlist.com/cgi/generic3/symbyax.htm

    Zyprexa Intramuscular FDA foglio

    Zyprexa_Intramuscular FDA

    Zyprexa Intramuscular DMS (foglio di materiale di sicurezza)

    Zyprexa Intramuscular Sintesi di riferimento

    Chakrabarti JK et al. US Pat. 5,229,382 (1991)

    Zyprexa Intramuscular Peso molecolare

    312.434 g/mol

    Zyprexa Intramuscular Temperatura di fusione

    195oC

    Zyprexa Intramuscular H2O Solubilita

    Nessuna informazione disponibile

    Zyprexa Intramuscular Stato

    Solid

    Zyprexa Intramuscular LogP

    2.199

    Zyprexa Intramuscular Forme di dosaggio

    Tablet (orale)

    Zyprexa Intramuscular Indicazione

    Per il trattamento della schizofrenia e psicosi maniaco-depressiva (disturbo bipolare).

    Zyprexa Intramuscular Farmacologia

    Olanzapina, un farmaco antipsicotico atipico, è usata per trattare sia i sintomi positivi e negativi della schizofrenia, mania acuta con disturbo bipolare, agitazione, sintomi psicotici e nella demenza. Futuro gli usi possono includere il trattamento del disturbo ossessivo-compulsivo e gravi disturbi comportamentali nell'autismo. Strutturalmente e farmacologicamente simile alla clozapina, olanzapina si lega per alfa (1), la dopamina, , H1 dell'istamina, muscarinici, e la serotonina di tipo 2 (5-HT2) recettori.

    Zyprexa Intramuscular Assorbimento

    Ben assorbito, con circa il 40% della dose è metabolizzato prima di raggiungere la circolazione sistemica.

    Zyprexa Intramuscular Tossicita

    Nessuna informazione disponibile

    Zyprexa Intramuscular Informazioni paziente

    PATIENT INFORMATION

    Physicians are advised to discuss the following issues with patients for whom they prescribe
    olanzapine:

    Orthostatic Hypotension: Patients should be advised of the risk of orthostatic hypotension,
    especially during the period of initial dose titration and in association with the use of
    concomitant drugs that may potentiate the orthostatic effect of olanzapine, e.g., diazepam
    or alcohol.

    Interference with Cognitive and Motor Performance: Because olanzapine has the potential to
    impair judgment, thinking, or motor skills, patients should be cautioned about operating
    hazardous machinery, including automobiles, until they are reasonably certain that olanzapine
    therapy does not affect them adversely.

    Pregnancy: Patients should be advised to notify their physician if they become pregnant or
    intend to become pregnant during therapy with olanzapine.

    Nursing: Patients should be advised not to breast-feed an infant if they are taking olanzapine.

    Concomitant Medication: Patients should be advised to inform their physicians if they are taking,
    or plan to take, any prescription or over-the-counter drugs, since there is a potential for
    interactions.

    Alcohol: Patients should be advised to avoid alcohol while taking olanzapine.

    Heat Exposure and Dehydration: Patients should be advised regarding appropriate care in avoiding
    overheating and dehydration.

    Phenylketonurics: ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) contains phenylalanine
    (0.34, 0.45, 0.67, or 0.90 mg per 5, 10, 15, or 20mg tablet, respectively).

    Laboratory Tests

    Periodic assessment of transaminases is recommended in patients with significant hepatic disease.

    Zyprexa Intramuscular Atto interessato organismi

    Gli esseri umani e altri mammiferi